Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly.
暂无分享,去创建一个
L. Dogliotti | F. Porpiglia | F. Di Carlo | M. Volante | A. Berruti | G. Reimondo | M. Terzolo | A. Angeli | B. Zaggia | E. Aroasio | A. Termine | F. Daffara | S. De Francia
[1] G. Hammer,et al. Management of adrenocortical carcinoma. , 2009, The Journal of the National Comprehensive Cancer Network.
[2] A. Berruti,et al. Adjunctive treatment of adrenocortical carcinoma , 2008, Current opinion in endocrinology, diabetes, and obesity.
[3] O. Nativ,et al. Adjuvant mitotane in adrenocortical carcinoma. , 2007, The New England journal of medicine.
[4] M. Papotti,et al. Adjuvant mitotane treatment for adrenocortical carcinoma. , 2007, The New England journal of medicine.
[5] D. Schteingart. Adjuvant mitotane therapy of adrenal cancer - use and controversy. , 2007, The New England journal of medicine.
[6] J. Bertherat,et al. Adrenocortical cancer: pathophysiology and clinical management. , 2007, Endocrine-related cancer.
[7] F. Ghezzo,et al. A new simple HPLC method for measuring mitotane and its two principal metabolites Tests in animals and mitotane-treated patients. , 2006, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[8] E. Baudin,et al. Mitotane has an estrogenic effect on sex hormone-binding globulin and corticosteroid-binding globulin in humans. , 2006, The Journal of clinical endocrinology and metabolism.
[9] S. Roman,et al. Adrenocortical carcinoma , 2006, Current opinion in oncology.
[10] E. Baudin,et al. Rapidly progressing high o,p'DDD doses shorten the time required to reach the therapeutic threshold with an acceptable tolerance: preliminary results , 2006, Clinical endocrinology.
[11] T. Giordano,et al. Management of patients with adrenal cancer: recommendations of an international consensus conference. , 2005, Endocrine-related cancer.
[12] M. Fassnacht,et al. Mitotane for adrenocortical carcinoma treatment. , 2005, Current opinion in investigational drugs.
[13] B. Skogseid,et al. Cytochrome P450-catalyzed binding of 3-methylsulfonyl-DDE and o,p'-DDD in human adrenal zona fasciculata/reticularis. , 2002, The Journal of clinical endocrinology and metabolism.
[14] E. Baudin,et al. Impact of monitoring plasma 1,1‐dichlorodiphenildichloroethane (o,p′DDD) levels on the treatment of patients with adrenocortical carcinoma , 2001, Cancer.
[15] Jeffrey E. Lee,et al. Adrenal cortical carcinoma , 2001, World Journal of Surgery.
[16] L. Dogliotti,et al. Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer. , 2000, The Journal of clinical endocrinology and metabolism.
[17] V. Budach,et al. [Adrenal cortical carcinoma]. , 1999, Zhonghua wai ke za zhi [Chinese journal of surgery].
[18] G. Dickstein. Is There a Role for Low Doses of Mitotane (o,p′,DDD) as Adjuvant Therapy in Adrenocortical Carcinoma?—Authors’ Response , 1999 .
[19] O. Nativ,et al. Is there a role for low doses of mitotane (o,p'-DDD) as adjuvant therapy in adrenocortical carcinoma? , 1998, The Journal of clinical endocrinology and metabolism.
[20] D. Vorojeikina,et al. Transcriptional activation of the human estrogen receptor by DDT isomers and metabolites in yeast and MCF-7 cells. , 1997, Biochemical pharmacology.
[21] A. Makowska,et al. Adrenocortical carcinoma. A clinical study and treatment results of 52 patients , 1995, Cancer.
[22] G. Fleuren,et al. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. , 1994, British Journal of Cancer.
[23] K. Hess,et al. Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer , 1993, Cancer.
[24] M. Wooten,et al. Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature , 1993, Cancer.
[25] M. Brennan,et al. An eleven-year experience with adrenocortical carcinoma. , 1992, Surgery.
[26] G. Thompson,et al. Possible mechanism and treatment of o,p'DDD-induced hypercholesterolaemia. , 1992, The Quarterly journal of medicine.
[27] A. Moolenaar,et al. Mitotane increases the blood levels of hormone-binding proteins. , 1991, Acta endocrinologica.
[28] P Blondeau,et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. , 1990, The New England journal of medicine.
[29] D. Cullen,et al. HEPATIC MICROSOMAL ENZYME INDUCTION AND ADRENAL CRISIS DUE TO o,p’DDD THERAPY FOR METASTATIC ADRENOCORTICAL CARCINOMA , 1989, Clinical endocrinology.
[30] L. Medeiros,et al. Pathologic Features of Prognostic Significance in Adrenocortical Carcinoma , 1989, The American journal of surgical pathology.
[31] S. Fukuchi,et al. [Effects of o,p'-DDD on pituitary-gonadal function in patients with Cushing's disease]. , 1988, Nihon Naibunpi Gakkai zasshi.
[32] M. Sparagana. Primary hypogonadism associated with o,p' DDD (mitotane) therapy. , 1987, Journal of toxicology. Clinical toxicology.
[33] L. Weiss. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors , 1984, The American journal of surgical pathology.
[34] K. Griffiths,et al. Steroids in saliva for assessing endocrine function. , 1982, Endocrine reviews.
[35] M. Boileau,et al. Adrenal cortical carcinoma. , 1978, The Journal of urology.
[36] W. Nicholson,et al. Effect of o,p'DDD on Human Adrenal Steroid llβ-Hydroxylation Activity , 1973 .
[37] W. Nicholson,et al. Effect of o,p'DDD on human adrenal steroid 11 beta-hydroxylation activity. , 1973, The Journal of clinical endocrinology and metabolism.
[38] L. S. Tompkins,et al. Effect of o,p'-DDD and similar compounds on thyroxine binding globulin. , 1968, The Journal of clinical endocrinology and metabolism.
[39] M. Lipsett,et al. CHEMOTHERAPY OF ADRENOCORTICAL CANCER WITH o,p′DDD , 1960 .